![]() |
|
|
Headed by Leroy Hood [University of Washington, Seattle (UWS)], an investigator in the Human Genome Project, the consortiums goals are to differentiate various forms of prostate cancer, determine the most effective methods of treatment for each, and eventually find a cure. CaP CURE (Cure of Cancer of the Prostate) was founded in 1992 by Michael Milken after the former financier was diagnosed with the disease. The consortium will identify and study families with an abnormally high incidence of prostate cancer, acquire and store high-quality prostate tissues for research, and support genetic and linkage studies leading to identification of the prostate cancer genes. Xenograft models will be used to develop extensive cDNA libraries of potential diagnostic and therapeutic compounds. Participating consortium institutions and their research functions are listed below. Tissue Banks: Dana Farber Cancer Institute, Boston; University of Texas M.D. Anderson Cancer Center, Houston; Washington University School of Medicine, St. Louis; and UWS Epidemiology: Fred Hutchinston Cancer Center, Seattle Genetic Mapping: Fred Hutchinson Cancer Center; Whitehead Institute MIT Center for Genome Research Expression Mapping: UWS; University of California, Los Angeles |


加入最爱